The Bigger the Ship, the Harder It Is to Turn: Continued Clinical Inertia With SGLT2i Utilization in Heart Failure

被引：0
|
作者：
Lyle, Melissa [1 ]
Santos-Gallego, Carlos G. [2 ]
机构：
[1] Mayo Clin, Div Adv Heart Failure & Transplant Cardiol, Jacksonville, FL 32224 USA
[2] Icahn Sch Med Mt Sinai, Cardiovasc Inst, Athero Thrombosis Res Unit, New York, NY USA
来源：
JOURNAL OF CARDIAC FAILURE | 2024年 / 30卷 / 09期
关键词：
EMPAGLIFLOZIN; OUTCOMES;
D O I：
10.1016/j.cardfail.2024.05.009
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1098 / 1099
页数：2
相关论文
共 50 条
  • [21] Overcoming clinical inertia with SGLT-2 inhibitors: Strategies to accelerate adoption in heart failure
    Crowe, Byron
    Misra, Shantum
    Lee, Clement D.
    JOURNAL OF HOSPITAL MEDICINE, 2024,
  • [22] The Growing Case for Use of SGLT2i in Heart Failure Additional Benefits of Empagliflozin in a HFpEF Rodent Model
    Ha, Chae-Myeong
    Wende, Adam R.
    JACC-BASIC TO TRANSLATIONAL SCIENCE, 2019, 4 (01): : 38 - 40
  • [23] Benefits of SGLT2i for the Treatment of Heart Failure Irrespective of Diabetes Diagnosis: A State-of-the-Art Review
    Delgado, Elias
    Jodar, Esteban
    Mezquita-Raya, Pedro
    Moreno-Perez, Oscar
    DIABETES THERAPY, 2022, 13 (SUPPL 1) : 19 - 34
  • [24] Uptake of SGLT2i therapyamongpatients hospitalized with heart failure: Insights from the veterans affairs healthcare system
    Calma, J.
    Varshney, A. S.
    Hernandez, M. Funes
    Hsiao, S.
    Sallam, K.
    Heidenreich, P. A.
    Sandhu, A. T.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [25] ECHOCARDIOGRAPHIC FINDING BETWEEN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION IN TREATMENT WITH ARNI AND SGLT2I
    Ceci, Vincenzo
    Mazzeo, Pietro
    Ferrara, Salvatore
    Nardella, Luigi
    Tricarico, Lucia
    Alfieri, Simona
    Croella, Francesca
    Amatruda, Marco
    Granatiero, Michele
    D'alessandro, Damiano
    Di Nunno, Nicola
    Pugliese, Rosanna
    Noviello, Giulia
    Correale, Michele
    Stabile, Egenio
    Stabile, Eugenio
    Iacoviello, Massimo
    Di Biase, Matteo
    Brunetti, Natale D.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2022, 24
  • [26] Benefits of SGLT2i for the Treatment of Heart Failure Irrespective of Diabetes Diagnosis: A State-of-the-Art Review
    Elías Delgado
    Esteban Jódar
    Pedro Mezquita-Raya
    Óscar Moreno-Pérez
    Diabetes Therapy, 2022, 13 : 19 - 34
  • [27] Risk of genitourinary infection similar among SGLT2i in patients with heart failure and preserved ejection fraction
    Reactions Weekly, 2024, 2011 (1) : 10 - 10
  • [28] Class effects of SGLT2 inhibitors (SGLT2i) in the heart: SGLT2i inhibit NHE, reduce [Na+]c and activate vasorelaxation in isolated mouse cardiomyocytes/hearts
    Uthman, L.
    Baartscheer, A.
    Bleijlevens, B.
    Schumacher, C. A.
    Fiolet, J. W. T.
    Koeman, A.
    Hollmann, M. W.
    Weber, N. C.
    Coronel, R.
    Zuurbier, C. J.
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2017, 109 : 59 - 59
  • [29] Improving management of heart failure with reduced ejection fraction with sglt2i's using the latest clinical data: an online education intervention
    Sattin, S.
    Sendaydiego, A. M.
    EUROPEAN HEART JOURNAL, 2021, 42 : 780 - 780
  • [30] Emerging Topics in Heart Failure: Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) in HF
    Bocchi, Edimar Alcides
    Biolo, Andrea
    Moura, Lidia Zytynski
    Figueiredo Neto, Jose Albuquerque
    Lucena Montenegro, Carlos Eduardo
    de Albuquerque, Denilson Campos
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2021, 116 (02)
12345